Early AMR pipeline looks beyond traditional antibiotics

21 Mar 2024
www.pharmaceutical-technology.com
Phase 1Orphan DrugImmunotherapy
Early AMR pipeline looks beyond traditional antibiotics
Preview
Source: Pharmaceutical Technology
Antimicrobial resistance (AMR) has been identified as a major global threat by the WHO. Image Credit: Inkoly / Shutterstock.
Despite being tagged as a global threat, the pipeline for new therapies against antimicrobial resistance (AMR)  is fairly weak, with most candidates in preclinical and early clinical development.
AMR has been identified as a major global threat by the World Health Organization (WHO). One of the reasons for the resistance is the overuse and misuse of antibiotics. Many reasons have been cited for an underdeveloped AMR pipeline, chief among them is a lack of commercial incentives.
The research into the development of new therapies against AMR was a key focus area at the 2024 ELRIG UK’s Research and Innovation – Drug Discovery (RI2024) conference that took place in Manchester from 20-21 March.
One of the most clinically advanced candidates in the lineup that was discussed at the meeting was Roche’s zosurabalpin. It is classified under a new antibiotic class of drugs called tethered macrocyclic peptides. Zosurabalpin targets the lipopolysaccharide (LPS) transport systems, which is important for maintaining bacterial cell structure among other functions.
The drug is being developed for the treatment of carbapenem-resistant acinetobacter baumanni (CRAB), which has been categorised as a ‘priority 1 pathogen’ by the WHO indicating an urgent need for therapies against these pathogens. Zosurabalpin was evaluated in Phase I trials in both healthy volunteers (NCT04605718) and critically ill patients with bacterial infections (NCT05614895) to determine the pharmacokinetics, safety, and tolerability of the drug.
See Also:
FDA grants orphan drug status to HI-Bio’s felzartamab for AMR
Early AMR pipeline looks beyond traditional antibiotics
Preview
Source: Pharmaceutical Technology
Trend report: how the market for prefilled syringes is evolving in 2024 (and beyond)
Early AMR pipeline looks beyond traditional antibiotics
Preview
Source: Pharmaceutical Technology
Another potential AMR therapy approach that was discussed at the meeting was patient-derived neutralising antibody therapy. One such therapy is being developed by the University of Cologne, wherein neutralising antibodies derived from patients with cystic fibrosis could be used against multi-drug resistant Pseudomonas aeruginosa, a common hospital infection. Patients with cystic fibrosis are most at risk of acquiring Pseudomonas infections. “We are currently looking for commercial partnerships to advance the therapy to Phase I trials,” said Alexander Simonis, one of the therapy developers and presenters.
Antibody therapies have been very successful as a cancer treatment, with multiple pharmaceutical companies investing in expanding their antibody portfolio.
Another novel AMR therapy was Glox Therapeutics’ bacteriocins, an engineered protein that targets drug-resistant pathogenic gram-negative bacteria such as Pseudomonas aeruginosa and Klebsiella pneumoniae. In November 2023, the University of Glasgow and University of Oxford-spinout raised £4.3m ($5.5m) in seed funding to develop bacteriocins against gram-negative bacteria.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.